Antiretroviral Therapy Offers Perinatal HIV Prevention

Antenatal ART significantly lowered early mother-to-child HIV transmission rates.

A triple-agent antenatal antiretroviral therapy (ART) produced significantly lower rates of early mother-to-child HIV transmission compared with zidovudine (ZDV). However, the treatment increased the risk for maternal adverse events and neonatal outcomes.

The PROMISE trial was conducted at 14 sites in 7 countries: India, Malawi, South Africa, Tanzania, Uganda, Zambia, and Zimbabwe. The study results were published in The New England Journal of Medicine.

Included in the study were HIV-infected women at 14 or more weeks of gestation, with a CD4 count of at least 350 cells per cubic millimeter. The participants were randomized to receive zidovudine and single-dose nevirapine plus a 1- to 2-week postpartum “tail” of tenofovir and emtricitabine (zidovudine alone); zidovudine, lamivudine, and lopinavir—ritonavir (zidovudine-based ART); or tenofovir, emtricitabine, and lopinavir–ritonavir (tenofovir-based ART).

All infants received nevirapine from birth until postpartum randomization, according to the study.

The primary outcomes were HIV transmission at 1 week of age in the infant, and maternal and infant safety. The secondary outcomes were defined as an infant being alive and not infected with HIV through the week 1 visit.

There were 3490 mother-infant sets included in the trial, of whom 65% were enrolled during period 1 and 35% during period 2. A majority of participants were African, young, and asymptomatic. At screening, the median CD4 count was 530 cells per cubic millimeter, and 3% of women were HBsAg-positive.

The results of the study showed that early transmission rates were significantly lower in the combined maternal ART groups than in the zidovudine monotherapy group (0.5% versus 1.8%; difference, -1.3 percentage points; repeated CI, -2.1 to -0.4). Furthermore, the rate of early transmission or death was significantly lower with zidovudine-based ART than with zidovudine monotherapy or tenofovir-based ART.

Despite these positive results, the rate of maternal grade 2 to 4 adverse events was significantly higher with zidovudine-based ART than with zidovudine monotherapy (21.1% versus 17.3%, P = 0.008). The rate of grade 2 to 4 abnormal blood chemical values was higher with tenofovir-based ART than with zidovudine monotherapy (2.9% versus 0.8%, P = 0.03), according to the study. No significant differences in adverse events were reported between the 2 ART groups.

A low birth rate less than 2500 g was found to be more frequent in women who received zidovudine-based ART compared with zidovudine monotherapy (23% versus 12%, P < 0.001), and more frequent with tenofovir-based ART compared with zidovudine monotherapy (16.9% vs. 8.9%, P = 0.004).

Preterm delivery before 37 weeks was more frequent with zidovudine-based ART than with zidovudine monotherapy (20.5% versus 13.1%, P < 0.001), according to the study. Tenofovir-based ART was associated with higher rates of very preterm delivery before 34 weeks (6% versus 2.6%, P = 0.04), and early infant death (4.4% versus 0.6%, P = 0.001), compared with zidovudine-based ART.

There were not significant differences observed between tenofovir-based ART and zidovudine monotherapy (P = 0.10 and P = 0.43). Additionally, the rate of HIV-free survival was highest among infants whose mothers received zidovudine-based ART.

Compared with zidovudine plus single-dose nevirapine, the triple-drug ART demonstrated superior efficacy for the prevention of mother-to-child transmission in HIV-infected women with a high CD4 cell count, but had higher rates of adverse events. The authors concluded that more research needs to be done to assess ART in pregnant women infected with HIV.

Related Videos
View All
Related Content
© 2023 MJH Life Sciences

All rights reserved.